H.C. Wainwright analyst Robert Burns lowered the firm’s price target on Caribou Biosciences to $26 from $27 and keeps a Buy rating on the shares post the Q4 results.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on CRBU:
- Caribou Biosciences price target lowered to $32 from $36 at Oppenheimer
- Caribou Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
- Caribou Biosciences reports Q4 EPS (44c), consensus (46c)
- Caribou Biosciences to Participate in the Oppenheimer 33rd Annual Healthcare Conference
- Caribou Biosciences to Participate in Upcoming Investor Conferences